Increasing data indicate that elevated intrahepatic or circulating PCSK-9 levels contribute to increased lipid storage in muscles and liver, adipose energy storage, hepatic fatty acids, and triglycerides storage, thereby promoting MASLD development [50]. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.